Abstract: The invention relates to a drug delivery device adapted for carrying and delivering both hydrophilic and lipophilic drug molecules. The drug delivery device includes a porous body for adsorption of drug molecules, the body including a plurality of microspheres, and a hydrogel forming cross-links connecting the plurality of microspheres.
Abstract: The invention provides antimicrobial polypeptides (AMPs) with high radial amphiphilicity. Unlike typical AMPs characterized by facial amphiphilicity or biomimetic antimicrobial polymers with randomly distributed charged and hydrophobic groups, these new AMPs are homo-polypeptides with radially amphiphilic structure. They adopt a stable ?-helical conformation with a hydrophobic helical core and a charged exterior shell, formed by flexible hydrophobic side chains with terminal charge group. The radially amphiphilic polypeptides offer several advantages over conventional AMPs with regard to stability against protease and simplicity of design. They also exhibit high antibacterial activity against both Gram-negative and Gram-positive bacteria and low hemolytic activity. The AMPs thus provide a general platform for treating drug-resistant bacterial infections.
Type:
Grant
Filed:
June 27, 2016
Date of Patent:
September 21, 2021
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
Jianjun Cheng, Menghua Xiong, Ziyuan Song
Abstract: A method of forming a stabilized calcium phosphate moiety for use in dental or biomedical applications includes providing a solution or dispersion including a calcium salt and reacting an organic phosphate having a polymerizable methacrylate or vinyl group with the solution or dispersion in order to form the calcium phosphate moiety having at least one pendant polymerizable group and at least one organic functional group, which may be the same group. A polymerizable composite system having a stabilized calcium phosphate formed according to the method is also provided.
Abstract: High shine single phase color cosmetic compositions that are flexible and resistant to water below a selected temperature, 43° C. for example. The compositions wear well, are smudge and flake resistant, as well as oil resistant, making them very suitable as high shine, long wear cosmetics. Compositions according to the invention comprise specific combinations of acrylates/VA copolymer and acrylates copolymer in a cosmetically acceptable base or delivery vehicle. Compositions according to the invention are hydrophilic and easily removed when scrubbed with water above a certain temperature, but not as easily removed with water below that temperature. The compositions are easy to manufacture, flexible and comfortable, and suitable for use on skin, hair and nails, particularly as eye shadow, eyeliner, lip products, tattoo products and mascara. Compositions may be formulated as liquid eyeliner, liquid eye shadow, mascara, liquid lip products and tattoo products.
Abstract: Disclosed herein is a use of a composition, comprising a non-toxic polyanionic material or a salt thereof to dissociate a polymeric membrane. In addition, a method of dissociating a polymeric membrane is also presented, the method comprising the steps of providing a polymeric membrane; and dissociating the polymeric membrane by adding a composition comprising a non-toxic polyanionic material to the polymeric membrane.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
August 31, 2021
Assignee:
Austrianova Singapore Pte Ltd.
Inventors:
Wee Jin Tan, Walter H. Gunzburg, John A. Dangerfield
Abstract: Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.
Type:
Grant
Filed:
April 4, 2014
Date of Patent:
August 24, 2021
Assignees:
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
Inventors:
Amy Strong, Stephen Boue, Matthew Burow, Bruce Bunnell, Quan Jiang, Shilong Zheng, Guangdi Wang
Abstract: The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.
Type:
Grant
Filed:
February 3, 2020
Date of Patent:
August 24, 2021
Assignee:
Currax Pharmaceuticals LLC
Inventors:
Luigi Schioppi, Brian Talmadge Dorsey, Michael Skinner, John Carter, Robert Mansbach, Philip Jochelson, Roberta L. Rogowski, Cara Baron Casseday, Meredith Perry, Bryan Knox
Abstract: This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas.
Type:
Grant
Filed:
July 20, 2016
Date of Patent:
August 10, 2021
Assignees:
The Brigham and Women's Hospital, Inc., The General Hospital Corporation
Abstract: The present invention relates in general to keratin treatment compositions and methods, and more specifically, compositions comprising up to 60% olefinic compounds and at least one unactivated double bond, the composition comprising fatty acid esters of polyhydric alcohols. The present invention is configured to be easily incorporated into bleaching processes, coloring processes, perming processes, shampoos, conditioners and/or styling products. The purpose of the invention is to provide a composition and method that will improve the overall health of keratins, in particular, texture, body, shine and strength.
Type:
Grant
Filed:
July 30, 2018
Date of Patent:
August 10, 2021
Inventors:
Joseph I. Kravitz, Sara M. Dreamer, Angelia J. Francis, Steve M. Hudson, Thomas D. Boatright
Abstract: The invention provides a novel class of materials that possess triplet-triplet annihilation upconversion, compositions and methods of preparation and use thereof. The invention also relates to use of such materials and nanoparticles, for example, in stimulus-responsive, in situ delivery of biologically active agents.
Abstract: An orthopedic implant having a metal surface and a calcium phosphate layer disposed on at least part of the metal surface is described. The calcium phosphate layer has an average crystallite size of less than about 100 nm in at least one direction and dissolves for more than 2 hours in vitro. The calcium phosphate layer is substantially free of carbonate. The coating, which is formed on a sodium titanate surface, has increased shear strength and tensile strength. The coating is formed by a solution deposited hydroxyapatite process under inert conditions. The pH of the solution varies by less than 0.1 pH unit/hour during coating formation.
Type:
Grant
Filed:
December 23, 2019
Date of Patent:
July 13, 2021
Assignee:
DePuy Synthes Products, Inc.
Inventors:
Rajendra Kasinath, Craig Ernsberger, Stephanie Vass, Steven N. Ginn, Haibo Qu, Weidong Tong
Abstract: A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
May 18, 2021
Assignee:
Micell Technologies, Inc.
Inventors:
James P. DeYoung, Charles Douglas Taylor, James B. McClain, Clint Smoke, Mike Cole
Abstract: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.
Type:
Grant
Filed:
May 31, 2019
Date of Patent:
May 11, 2021
Assignee:
THE UNIVERSITY OF KANSAS
Inventors:
Michael Detamore, Emily Beck, Stevin Gehrke, Cory Berkland
Abstract: Embodiments of the disclosure include lubricious coatings. In an embodiment the disclosure includes a lubricious coating for a medical device including first and second coated layers. The first coated layer is between the second coated layer and the device surface and includes a vinyl pyrrolidone polymer and a photo reactive group. The second coated layer is in direct contact with the first coated layer and is a top coating that includes an acrylic acid polymer. The second coated layer can optionally include photoreactive groups. The coating was found to have a very low number of particulates (e.g., 10 ?m or greater) which is very desirable for in vivo use.
Type:
Grant
Filed:
January 6, 2014
Date of Patent:
May 11, 2021
Assignee:
Surmodics, Inc.
Inventors:
David E. Babcock, Timothy M. Kloke, Joseph S. McGonigle
Abstract: The present invention relates to an anhydrous composition in aerosol form comprising, in particular in a physiologically acceptable medium: a) an oily phase comprising i) at least one volatile oil, and ii) at least one nonvolatile hydrocarbon-based oil, and iii) at least one phenyl silicone, and b) at least one antiperspirant active agent chosen from aluminum and/or zirconium salts or complexes, c) at least one water-insoluble film-forming block ethylenic polymer d) at least one propellant. The invention also relates to a cosmetic process for treating human perspiration, and optionally the body odors associated with human perspiration, especially underarm odors, comprising the application of said composition to a surface of the skin.
Abstract: A method for preparing a hydrogel comprising mixing a solution of a polymer with a photoinitiator, where the polymer comprises multiple subunits each having a non-aromatic unsaturated functional group, and irradiating the mixture with visible light to produce the hydrogel.
Type:
Grant
Filed:
December 2, 2016
Date of Patent:
May 4, 2021
Assignee:
Otago Innovation Limited
Inventors:
Shen Khoon Lim, Timothy Bryan Francis Woodfield, Gabriella Christina Johanna Lindberg
Abstract: Compositions and methods of making a modified polyhydroxylated polymer comprising a polyhydroxylated polymer having reversibly modified hydroxyl groups, whereby the hydroxyl groups are modified by an acid-catalyzed reaction between a polydroxylated polymer and a reagent such as acetals, aldehydes, vinyl ethers and ketones such that the modified polyhydroxylated polymers become insoluble in water but freely soluble in common organic solvents allowing for the facile preparation of acid-sensitive materials. Materials made from these polymers can be made to degrade in a pH-dependent manner. Both hydrophobic and hydrophilic cargoes were successfully loaded into particles made from the present polymers using single and double emulsion techniques, respectively. Due to its ease of preparation, processability, pH-sensitivity, and biocompatibility, of the present modified polyhydroxylated polymers should find use in numerous drug delivery applications.
Type:
Grant
Filed:
March 30, 2017
Date of Patent:
May 4, 2021
Assignee:
The Regents of the University of California
Inventors:
Jean M. J. Frechet, Eric M. Bachelder, Tristan T. Beaudette, Kyle E. Broaders
Abstract: Embodiments of the disclosure include lubricious coatings. In an embodiment the disclosure includes a lubricious coating for a medical device including first and second coated layers. The first coated layer is between the second coated layer and the device surface and includes a vinyl pyrrolidone polymer and a photo reactive group. The second coated layer is in direct contact with the first coated layer and is a top coating that includes an acrylic acid polymer. The second coated layer can optionally include photoreactive groups. The coating was found to have a very low number of particulates (e.g., 10 ?m or greater) which is very desirable for in vivo use.
Type:
Grant
Filed:
February 29, 2016
Date of Patent:
April 20, 2021
Assignee:
Surmodics, Inc.
Inventors:
David E. Babcock, Timothy M. Kloke, Joseph S. McGonigle, Nathan Lockwood, Bruce Jelle
Abstract: There is provided a gel composition that can be suitably used as a thickener for cosmetic preparations and the like. A gel composition comprising a neutralized product of an alkyl-modified carboxyl group-containing polymer, which is a copolymer of monomers comprising 100 parts by mass of (meth)acrylic acid (a), 2.5 to 5 parts by mass of a (meth)acrylic acid alkyl ester (b) in which the alkyl group has 18 to 24 carbon atoms, and 0.1 part by mass or less of a compound (c) having two or more ethylenically unsaturated groups; and at least one of an anionic emulsifier and a nonionic emulsifier.
Abstract: The present invention provides a pharmaceutical composition containing a pyrrolo-fused six-membered heterocyclic compound or a pharmaceutically acceptable salt of the compound. Specifically, the invention provides a pharmaceutical composition containing 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof, and at least one water soluble filler. The pharmaceutical composition of the invention features a rapid dissolution and good stability.
Type:
Grant
Filed:
February 28, 2017
Date of Patent:
April 13, 2021
Assignee:
Jiangsu Hengrui Medicine Co., Ltd.
Inventors:
Yun Lu, Xinhua Zhang, Chenyang Wang, Tonghui Liu